Clinical Trials Compliance THC Treatment 
MMJ Recs
APRIL 1, 2024
We’re exploring the world of CBD, uncovering the benefits of CBD in medical marijuana, its impact on health, its potential as a treatment option, and what you need to know about its use in medical marijuana. CBD: A Promising Treatment Option One of the most compelling aspects of CBD is its versatility as a treatment option.
MMJ Recs
DECEMBER 17, 2023
Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. THC is the psychoactive compound responsible for the “high” associated with marijuana use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JULY 4, 2021
The level of THC in CBD products should fall below 0.2% Also, alone it won’t create the “high” sensation associated with the use of Tetrahydrocannabinol or THC. Clinical trials across the EU have also shown CBD oils and other hemp products to have a potential range of benefits. What is THC? CBD vs THC.
Veriheal
OCTOBER 13, 2020
Cannabis has been identified as an effective alternative treatment for some gastrointestinal disorders…but does that include IBD and IBS? . Diet is used as the primary treatment. . Dronabinol is commonly used as a treatment in cancer patients due to the fact that it can decrease gut transit and increase colon compliance.
Cannabis Law Report
NOVEMBER 12, 2021
Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. In compliance with current Good Manufacturing Practice requirements, the Company delivered ANEB-001’s active pharmaceutical ingredient to its contract manufacturer to fill into 10 mg and 50 mg capsules for finished product.
Cannabis Law Report
AUGUST 21, 2019
Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. If you wish to re-publish this story please do so with following accreditation. AUTHOR: Mark Taylor.
Cannabis Law Report
JULY 14, 2021
(“ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. ImmunoFlex’s believes that the immune system changes observed in this clinical study are beneficial changes with the potential to improve immune system competence. federal law.
Expert insights. Personalized for you.
52 
Let's personalize your content